This “RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in RET (Ret Proto-Oncogene) protein Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
RET (Ret Proto-Oncogene) protein Inhibitor Understanding
RET is a transmembrane receptor protein-tyrosine kinase that is required for the development of the nervous system and several other tissues. The mechanism of activation of RET by its glial-cell derived neurotrophic factor (GDNF) ligands differs from that of all other receptor protein-tyrosine kinases owing to the requirement for additional GDNF family receptor-α (GFRα) co-receptors (GFRα1/2/3/4). RET point mutations have been reported in multiple endocrine neoplasia (MEN2A, MEN2B) and medullary thyroid carcinoma. In contrast, RET fusion proteins have been reported in papillary thyroid and non-small cell lung adenocarcinomas. More than a dozen fusion partners of RET have been described in papillary thyroid carcinomas, most frequently CCDC6-RET and NCOA4-RET. RET-fusion proteins, commonly KIF5B-RET, have also been found in non-small cell lung cancer (NSCLC). Several drugs targeting RET have been approved by the FDA for the treatment of cancer: cabozantinib and vandetanib for medullary thyroid carcinomas and lenvatinib and sorafenib for differentiated thyroid cancers. In addition, alectinib and sunitinib are approved for the treatment of other neoplasms.
RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2022 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the RET (Ret Proto-Oncogene) protein Inhibitor pipeline landscape is provided which includes the disease overview and RET (Ret Proto-Oncogene) protein Inhibitor treatment guidelines. The assessment part of the report embraces, in depth RET (Ret Proto-Oncogene) protein Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, RET (Ret Proto-Oncogene) protein Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the RET (Ret Proto-Oncogene) protein Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
RET (Ret Proto-Oncogene) protein Inhibitor Emerging Drugs
Sitravatinib: Mirati Therapeutics
Sitravatinib is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. Sitravatinib is being evaluated in combination with nivolumab (OPDIVO), an anti-PD-1 checkpoint inhibitor, in patients whose cancers have progressed despite treatment with a checkpoint inhibitor. Sitravatinib is being evaluated in multiple clinical trials to treat patients who are resistant to prior immune checkpoint inhibitor therapy and progressed on platinum doublet therapy, including the ongoing potentially registration-enabling Phase III trial of sitravatinib in combinations with a checkpoint inhibitor in non-small cell lung cancer (NSCLC). In addition, sitravatinib in combination with checkpoint inhibitors are being evaluated in selected checkpoint inhibitor naïve patients.
Zeteletinib: Boston Pharmaceuticals
Zeteletinib is a small molecule, highly selective and potent RET (ret proto-oncogene) kinase inhibitor. In August 2017, Daiichi Sankyo Company and Boston Pharmaceuticals announced that they have entered into a worldwide licensing agreement for Daiichi Sankyo's novel RET inhibitor, DS-5010.
This segment of the report provides insights about the different RET (Ret Proto-Oncogene) protein Inhibitor drugs segregated based on following parameters that define the scope of the report.
There are approx. 12+ key companies which are developing the therapies for RET (Ret Proto-Oncogene) protein Inhibitor. The companies which have their RET (Ret Proto-Oncogene) protein Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Mirati Therapeutics.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
RET (Ret Proto-Oncogene) protein Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses RET (Ret Proto-Oncogene) protein Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging RET (Ret Proto-Oncogene) protein Inhibitor drugs.
Geography Covered
- Global coverage
RET (Ret Proto-Oncogene) protein Inhibitor Understanding
RET (Ret Proto-Oncogene) protein Inhibitor: Overview
RET is a transmembrane receptor protein-tyrosine kinase that is required for the development of the nervous system and several other tissues. The mechanism of activation of RET by its glial-cell derived neurotrophic factor (GDNF) ligands differs from that of all other receptor protein-tyrosine kinases owing to the requirement for additional GDNF family receptor-α (GFRα) co-receptors (GFRα1/2/3/4). RET point mutations have been reported in multiple endocrine neoplasia (MEN2A, MEN2B) and medullary thyroid carcinoma. In contrast, RET fusion proteins have been reported in papillary thyroid and non-small cell lung adenocarcinomas. More than a dozen fusion partners of RET have been described in papillary thyroid carcinomas, most frequently CCDC6-RET and NCOA4-RET. RET-fusion proteins, commonly KIF5B-RET, have also been found in non-small cell lung cancer (NSCLC). Several drugs targeting RET have been approved by the FDA for the treatment of cancer: cabozantinib and vandetanib for medullary thyroid carcinomas and lenvatinib and sorafenib for differentiated thyroid cancers. In addition, alectinib and sunitinib are approved for the treatment of other neoplasms.
RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2022 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the RET (Ret Proto-Oncogene) protein Inhibitor pipeline landscape is provided which includes the disease overview and RET (Ret Proto-Oncogene) protein Inhibitor treatment guidelines. The assessment part of the report embraces, in depth RET (Ret Proto-Oncogene) protein Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, RET (Ret Proto-Oncogene) protein Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence RET (Ret Proto-Oncogene) protein Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve RET (Ret Proto-Oncogene) protein Inhibitor.
RET (Ret Proto-Oncogene) protein Inhibitor Emerging Drugs Chapters
This segment of the RET (Ret Proto-Oncogene) protein Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
RET (Ret Proto-Oncogene) protein Inhibitor Emerging Drugs
Sitravatinib: Mirati Therapeutics
Sitravatinib is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. Sitravatinib is being evaluated in combination with nivolumab (OPDIVO), an anti-PD-1 checkpoint inhibitor, in patients whose cancers have progressed despite treatment with a checkpoint inhibitor. Sitravatinib is being evaluated in multiple clinical trials to treat patients who are resistant to prior immune checkpoint inhibitor therapy and progressed on platinum doublet therapy, including the ongoing potentially registration-enabling Phase III trial of sitravatinib in combinations with a checkpoint inhibitor in non-small cell lung cancer (NSCLC). In addition, sitravatinib in combination with checkpoint inhibitors are being evaluated in selected checkpoint inhibitor naïve patients.
Zeteletinib: Boston Pharmaceuticals
Zeteletinib is a small molecule, highly selective and potent RET (ret proto-oncogene) kinase inhibitor. In August 2017, Daiichi Sankyo Company and Boston Pharmaceuticals announced that they have entered into a worldwide licensing agreement for Daiichi Sankyo's novel RET inhibitor, DS-5010.
RET (Ret Proto-Oncogene) protein Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different RET (Ret Proto-Oncogene) protein Inhibitor drugs segregated based on following parameters that define the scope of the report.
Major Players in RET (Ret Proto-Oncogene) protein Inhibitor
There are approx. 12+ key companies which are developing the therapies for RET (Ret Proto-Oncogene) protein Inhibitor. The companies which have their RET (Ret Proto-Oncogene) protein Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Mirati Therapeutics.
Phases
This report covers around 12+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
RET (Ret Proto-Oncogene) protein Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
RET (Ret Proto-Oncogene) protein Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses RET (Ret Proto-Oncogene) protein Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging RET (Ret Proto-Oncogene) protein Inhibitor drugs.
RET (Ret Proto-Oncogene) protein Inhibitor Report Insights
- RET (Ret Proto-Oncogene) protein Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
RET (Ret Proto-Oncogene) protein Inhibitor Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing RET (Ret Proto-Oncogene) protein Inhibitor drugs?
- How many RET (Ret Proto-Oncogene) protein Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of RET (Ret Proto-Oncogene) protein Inhibitor?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the RET (Ret Proto-Oncogene) protein Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for RET (Ret Proto-Oncogene) protein Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Boston Pharmaceuticals
- Mirati Therapeutics
- Sitravatinib
- Voronoi
- GrayBug Vision
Key Products
- BOS 172738
- Sitravatinib
- Pralsetinib
- VRN-06
- GB 102
Table of Contents
IntroductionExecutive Summary
RET (Ret Proto-Oncogene) protein Inhibitor: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Sitravatinib: Mirati Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I)
- Comparative Analysis
BOS 172738: Boston Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Preclinical stage products
- Comparative Analysis
VRN-06: Voronoi
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
RET (Ret Proto-Oncogene) protein Inhibitor Key Companies
RET (Ret Proto-Oncogene) protein Inhibitor Key Products
RET (Ret Proto-Oncogene) protein Inhibitor- Unmet Needs
RET (Ret Proto-Oncogene) protein Inhibitor- Market Drivers and Barriers
AppendixList of Tables
Table 1 Total Products for RET (Ret Proto-Oncogene) protein Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for RET (Ret Proto-Oncogene) protein Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Boston Pharmaceuticals
- Mirati Therapeutics
- Blueprint Medicines
- Voronoi
- GrayBug Vision
